8-K: Know Labs Cancels Special Stockholder Meeting Following Reverse Stock Split

Know Labs cancels its special stockholder meeting scheduled for March 7, 2025, after implementing a 1-for-40 reverse stock split.

Summary

• Know Labs, Inc. announced the cancellation of its special meeting of stockholders previously scheduled for March 7, 2025.
• The meeting was intended to seek approval for a reverse stock split.
• The cancellation follows the company's announcement of a 1-for-40 reverse stock split of its common stock on February 18, 2025, which became effective on February 19, 2025.
• The reverse stock split did not require stockholder approval due to the Board's authority under Nevada law, as the number of authorized and outstanding shares were proportionally reduced.
• The company's stock began trading on a post-split basis on the OTC Pink Market under the temporary symbol KNWND on February 19, 2025, for a period of 20 days.
• The company's technology uses radio frequency spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature.
• The company's first expected application of the technology will be in a product marketed as a non-invasive glucose monitor, which will require FDA clearance prior to its introduction to the market.

Sentiment

Score: 5

Explanation: The news is neutral. The cancellation of the meeting is procedural following the reverse stock split. The company's future prospects depend on the successful development and commercialization of its technology.

Positives

• The company successfully executed a reverse stock split, which could potentially make the stock more attractive to some investors.
• The company's technology has potential applications in various wearable, mobile or bench-top form factors.
• The company's first expected application of the technology will be in a product marketed as a non-invasive glucose monitor, which will require FDA clearance prior to its introduction to the market.

Negatives

• The company's stock is trading on the OTC Pink Market, which is generally considered a less reputable market than major exchanges.
• The company's first expected application of the technology will be in a product marketed as a non-invasive glucose monitor, which will require FDA clearance prior to its introduction to the market.

Risks

• The company's future performance is subject to risks and uncertainties, including those discussed in its filings with the SEC.
• The company's non-invasive glucose monitor will require FDA clearance prior to its introduction to the market, which is not guaranteed.
• The company's technology may not be successful in identifying and monitoring analytes as expected.

Future Outlook

The company intends to continue developing and commercializing its RFDS technology, with a focus on its non-invasive glucose monitor. The company also plans to expand its technology licensing division, KTL.

Industry Context

The development of non-invasive glucose monitoring technology is a competitive field, with numerous companies and research institutions working to develop accurate and reliable devices. Know Labs' RFDS technology represents a novel approach to this challenge.

Stakeholder Impact

• Shareholders are impacted by the reverse stock split and the cancellation of the special meeting.
• The company's employees are impacted by the company's strategic decisions and future prospects.
• Customers may benefit from the development of the company's non-invasive glucose monitor.
• The company's suppliers and creditors are impacted by the company's financial performance and future prospects.

Next Steps

• The company will continue to develop and commercialize its RFDS technology.
• The company will seek FDA clearance for its non-invasive glucose monitor.
• The company will continue to expand its technology licensing division, KTL.

Key Dates